Climb Bio, Inc. (CLYM) vs MiMedx Group, Inc. (MDXG)
A side-by-side comparison of Climb Bio, Inc. and MiMedx Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLYM
Climb Bio, Inc.
$11.23HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
MDXG
MiMedx Group, Inc.
$4.60HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Total return — CLYM vs MDXG
growth of $100 · dividends reinvested · last 2yCLYM +41.1% (+18.8%/yr)MDXG -26.0% (-14.0%/yr)CLYM compounded faster over this window
CLYM MDXG
CLYM vs MDXG: by the numbers
- •MDXG is the larger company ($670M vs $643M market cap).
- •MDXG is profitable (1.76% net margin) while CLYM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CLYM | MDXG |
|---|---|---|
| P/E ratio | N/A | 114.94 |
| P/S ratio | N/A | 1.89 |
| P/B ratio | 2.68 | 3.10 |
| EV / EBITDA | N/A | 26.25 |
| FCF yield | N/A | 6.05% |
Profitability
| Metric | CLYM | MDXG |
|---|---|---|
| Gross margin | 0.00% | 78.85% |
| Operating margin | 0.00% | 15.26% |
| Net margin | 0.00% | 1.76% |
| ROE | -24.06% | 2.89% |
| ROIC | -26.94% | 1.97% |
Growth (annualized)
| Metric | CLYM | MDXG |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 6.36% |
| Total return CAGR (5Y) | N/A | -4.94% |
Frequently asked
- Is CLYM or MDXG more profitable?
- MDXG runs the higher net margin — CLYM at 0.00% versus MDXG at 1.76%.
Go deeper
Dig into the metrics
MiMedx P/E ratioClimb Bio ROEMiMedx ROEClimb Bio operating marginMiMedx operating marginClimb Bio revenue growthMiMedx revenue growthClimb Bio free cash flowMiMedx free cash flow
Climb Bio & MiMedx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.